<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36997975</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-7529</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Research involvement and engagement</Title><ISOAbbreviation>Res Involv Engagem</ISOAbbreviation></Journal><ArticleTitle>Co-production of a feasibility trial of pacing interventions for Long COVID.</ArticleTitle><Pagination><StartPage>18</StartPage><MedlinePgn>18</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40900-023-00429-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The high incidence of COVID-19 globally has led to a large prevalence of Long COVID but there is a lack of evidence-based treatments. There is a need to evaluate existing treatments for symptoms associated with Long COVID. However, there is first a need to evaluate the feasibility of undertaking randomised controlled trials of interventions for the condition. We aimed to co-produce a feasibility study of non-pharmacological interventions to support people with Long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A consensus workshop on research prioritisation was conducted with patients and other stakeholders. This was followed by the co-production of the feasibility trial with a group of patient partners, which included the design of the study, the selection of interventions, and the production of dissemination strategies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The consensus workshop was attended by 23 stakeholders, including six patients. The consensus from the workshop was to develop a clinical trial platform that focused on testing different pacing interventions and resources. For the co-production of the feasibility trial, patient partners selected three pacing resources to evaluate (video, mobile application, and book) and co-designed feasibility study processes, study materials and undertook usability testing of the digital trial platform.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In conclusion, this paper reports the principles and process used to co-produce a feasibility study of pacing interventions for Long COVID. Co-production was effective and influenced important aspects of the study.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Grace M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMullan</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiyegbusi</LastName><ForeName>Olalekan Lee</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeyes</LastName><ForeName>Felicity</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Patient Partner, Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Patient Partner, Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Patient Partner, Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckland</LastName><ForeName>Lewis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Patient Partner, Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Patient Partner, Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Elin Haf</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Aparito Ltd, Wrexham, Wales.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroon</LastName><ForeName>Shamil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvert</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_20050</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Res Involv Engagem</MedlineTA><NlmUniqueID>101708164</NlmUniqueID><ISSNLinking>2056-7529</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>The World Health Organisation defines Long COVID as a condition which impacts people 3 months after they first had COVID-19. Some of the symptoms that characterise Long COVID symptoms include fatigue, breathlessness and brain fog. These symptoms have a major impact on people&#x2019;s health and quality of life. Today, over 2 million people in the United Kingdom suffer from Long COVID and there is a lack of drugs and non-drugs treatment. However, some non-drugs treatments which aim to manage fatigue in other conditions, such as pacing, could be used with people with Long COVID. In this paper, we report how we co-produced a study which tested whether or not it is feasible for people who have Long COVID to use a pacing resource and report their symptoms using an electronic platform. After a meeting to review existing non-drugs treatments, the research team and a group of patient partners agreed on co-developing a clinical trial platform to test different pacing resources. The research team then met with the patient partners twice a week to co-design the study during which people with Long COVID will use the pacing resources and report their symptoms. They also co-designed the study documents and how to report its results. Co-producing a study with patient partners was effective and influenced important aspects of the study.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coproduction</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Feasibility</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Pacing</Keyword><Keyword MajorTopicYN="N">Patient and public involvement</Keyword><Keyword MajorTopicYN="N">Post Covid-19 condition</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 infection (PASC)</Keyword></KeywordList><CoiStatement>GMT receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI). CM receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), UKRI, and declares personal fees from Aparito Ltd outside the submitted work. SEH receives funding from the NIHR Oxford-Birmingham Blood and Transplant Research Unit (BTRU) in Precision Cellular Therapeutics, NIHR ARC West Midlands at the University of Birmingham, UK SPINE and UKRI. SEH has received personal fees from Cochlear Ltd, Astra Zeneca, ICON, and Aparito Ltd outside the submitted work. OLA receives funding from the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, NIHR ARC West Midlands at the University of Birmingham, the Brain Tumour Charity, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals Inc. OLA declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. MJC is a NIHR Senior Investigator, receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, European Regional Development Fund&#x2014;Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK and Gilead Sciences. MJC receives personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK, ICON and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. SH receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36997975</ArticleId><ArticleId IdType="pmc">PMC10061378</ArticleId><ArticleId IdType="doi">10.1186/s40900-023-00429-2</ArticleId><ArticleId IdType="pii">10.1186/s40900-023-00429-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>(ONS) OfNS. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2022.</Citation></Reference><Reference><Citation>WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Clinical management of COVID-19: Living guideline. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35917394</ArticleId></ArticleIdList></Reference><Reference><Citation>ME Af. Pacing for people with ME2019.</Citation></Reference><Reference><Citation>Chandan JS, Brown KR, Simms-Williams N, Bashir NZ, Camaradou J, Heining D, et al. Non-pharmacological therapies for post-viral syndromes, including Long COVID: a systematic review. Int J Environ Res Public Health. 2023;20(4):3477. doi: 10.3390/ijerph20043477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph20043477</ArticleId><ArticleId IdType="pmc">PMC9967466</ArticleId><ArticleId IdType="pubmed">36834176</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon S, Nirantharakumar K, Hughes SE, Subramanian A, Aiyegbusi OL, Davies EH, et al. Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study) BMJ Open. 2022;12(4):e060413. doi: 10.1136/bmjopen-2021-060413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-060413</ArticleId><ArticleId IdType="pmc">PMC9044550</ArticleId><ArticleId IdType="pubmed">35473737</ArticleId></ArticleIdList></Reference><Reference><Citation>NIHR. Guidance on co-producing a research project. 2018.</Citation></Reference><Reference><Citation>NIHR. UK Standards for Public Involvement. 2019.</Citation></Reference><Reference><Citation>Liu Y, Yu Q, Wen H, Shi F, Wang F, Zhao Y, et al. What matters: non-pharmaceutical interventions for COVID-19 in Europe. Antimicrob Resist Infect Control. 2022;11(1):3. doi: 10.1186/s13756-021-01039-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-021-01039-x</ArticleId><ArticleId IdType="pmc">PMC8743060</ArticleId><ArticleId IdType="pubmed">35000583</ArticleId></ArticleIdList></Reference><Reference><Citation>Abonie US, Sandercock GRH, Heesterbeek M, Hettinga FJ. Effects of activity pacing in patients with chronic conditions associated with fatigue complaints: a meta-analysis. Disabil Rehabil. 2020;42(5):613&#x2013;622. doi: 10.1080/09638288.2018.1504994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2018.1504994</ArticleId><ArticleId IdType="pubmed">30449204</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Marrero J, Saez-Francas N, Santillo D, Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. Br J Pharmacol. 2017;174(5):345&#x2013;369. doi: 10.1111/bph.13702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13702</ArticleId><ArticleId IdType="pmc">PMC5301046</ArticleId><ArticleId IdType="pubmed">28052319</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. COVID-19 rapid guideline: managing the longterm effects of COVID-19. 2021.</Citation></Reference><Reference><Citation>Alliance JL. The JLA Guidebook, Chapter 8: Final Priority Settings. 2019.</Citation></Reference><Reference><Citation>Foundation W. ME/CFS activity management with a heart rate monitor. https://workwellfoundation.org/wp-content/uploads/2021/03/HRM-Factsheet.pdf.</Citation></Reference><Reference><Citation>Hughes SE, Haroon S, Subramanian A, McMullan C, Aiyegbusi OL, Turner GM, et al. Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BMJ. 2022;377:e070230. doi: 10.1136/bmj-2022-070230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070230</ArticleId><ArticleId IdType="pmc">PMC9043395</ArticleId><ArticleId IdType="pubmed">35477524</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell T, Best P, Davidson G, McEneaney T, Cantrell C, Tully M. Coproduction for feasibility and pilot randomised controlled trials: learning outcomes for community partners, service users and the research team. Res Involv Engagem. 2018;4:32. doi: 10.1186/s40900-018-0116-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40900-018-0116-0</ArticleId><ArticleId IdType="pmc">PMC6174568</ArticleId><ArticleId IdType="pubmed">30338129</ArticleId></ArticleIdList></Reference><Reference><Citation>Biggane AM, Olsen M, Williamson PR. PPI in research: a reflection from early stage researchers. Res Involv Engagem. 2019;5:35. doi: 10.1186/s40900-019-0170-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40900-019-0170-2</ArticleId><ArticleId IdType="pmc">PMC6865031</ArticleId><ArticleId IdType="pubmed">31832239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan JS, Brown KR, Simms-Williams N, Bashir NZ, Camaradou J, Heining D, et al. Non-pharmacological therapies for post-viral syndromes, including Long COVID: a systematic review. medRxiv. 2022:2022.06.07.22276080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9967466</ArticleId><ArticleId IdType="pubmed">36834176</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GP. 'Ordinary people only': knowledge, representativeness, and the publics of public participation in healthcare. Sociol Health Illn. 2008;30(1):35&#x2013;54. doi: 10.1111/j.1467-9566.2007.01027.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-9566.2007.01027.x</ArticleId><ArticleId IdType="pubmed">18254832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampa E, Sonnentheil B, Tokes A, Warner G. What has the COVID-19 pandemic taught us about conducting patient and public involvement remotely? Insights from a series of digital meeting observations. Res Involv Engagem. 2021;7(1):73. doi: 10.1186/s40900-021-00315-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40900-021-00315-9</ArticleId><ArticleId IdType="pmc">PMC8503706</ArticleId><ArticleId IdType="pubmed">34635179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>